alexa Novel Cell Replacement Strategies for Heart Failure Treatment | Open Access Journals
Atherosclerosis: Open Access
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Novel Cell Replacement Strategies for Heart Failure Treatment

Tamer MA Mohamed*

Cardiovascular Research Institute, Faculty of Medical and Human Sciences, University of Manchester, UK

*Corresponding Author:
Tamer M A Mohamed
Cardiovascular Research Institute
Faculty of Medical and Human Sciences
University of Manchester, UK
Tel: 001-415-9711459
[email protected]

Received Date: November 9, 2015 Accepted Date: June 03, 2016 Published Date: June 10, 2016

Citation: Mohamed TMA (2015) Novel Cell Replacement Strategies for Heart Failure Treatment. Atheroscler open access 1:102. doi: 10.4172/asoa.1000102

Copyright: © 2015 Mohamed TM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Atherosclerosis: Open Access

Heart failure treatment

Myocardial infarction (MI), or heart attack, is caused by the blockage of blood flow in the heart, which reduces oxygen levels, damages tissues (ischemia) and kills close to one billion cardiomyocytes (infarction) [1]. Fibroblasts then migrate into the infarcted area where they proliferate to create a cardiomyocytedepleted scar that cannot contribute to the electrophysiologicallydriven contractions of the heart. This often causes HF leading to fatigue, peripheral edema, or even death. To find more effective therapies for HF, we need to improve our understanding of its pathophysiology and develop new approaches to treating it.

Cell-replacement therapy has emerged as a novel approach to treat HF. This approach relies on the theory that after MI or in HF, lost cardiomyocytes can be replaced by adding either new cardiomyocytes or a potential source of cardiomyocytes such as stem cells. To find the most effective approach, researchers have tested several types of stem cells including skeletal myoblasts [2], cardiac progenitor cells [3], and mesenchymal stem cells from bone marrow [4]. However, they have only been modestly successful because the beneficial effects are mainly mediated by indirect paracrine mechanisms: stem cells do not transdifferentiate into cardiomyocytes in-vivo and the number of stem cells retained in the heart after delivery is disappointingly low [5]. Fortunately, cell-replacement therapy for HF using pluripotent stemcell- derived cardiomyocytes showed more promising results in rodents and non-human primates because they integrate and electrically couple with the healthy myocardium [6-8]. However, technologies involving stem-cell-derived cardiomyocytes must be further optimized before they can effectively treat HF. Specifically, we need to find methods that improve the efficiency and consistency of cardiomyocyte differentiation in large scale, their survival in disease conditions, their integration into cardiac tissue, and their resistance to autoimmune rejection.

Recently, Srivastava laboratory and others demonstrated an alternative approach-transdifferentiation of resident cardiac fibroblasts (CFs) into cardiomyocytes, called direct cardiac reprogramming. They initially illustrated that CFs transdifferentiate into a more cardiac-like state both in-vitro and in-vivo when treated with a combination of three transcription factors associated with cardiogenesis-Gata4, Mef2c, and Tbx5 (GMT) [9]. Building on this technology, subsequent reports have shown that various combinations of transcription factors, and microRNAs and other combinations [10-13]. However, the efficiency of reprogramming and extent of cardiac-specific gene expression and morphology, such as sarcomere organization, have been consistently better in-vivo than in-vitro [14,15].

In fact, reprogramming CFs in-vivo improved cardiac function after injury (e.g., ejection fraction, cardiac output, and stroke volume) [14, 15]. While reprogramming the pool of endogenous cardiac fibroblasts into cardiomyocyte-like cells is a promising approach for cardiac regeneration, the methods must be refined to enhance the efficiency and quality of their reprogramming. Thus, we must understand the mechanism by which the reprogramming factors fundamentally alter the cell state. This work is currently conducted by various groups around the world to identify the barriers for cell transdifferentiation.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 7928
  • [From(publication date):
    June-2016 - Sep 20, 2017]
  • Breakdown by view type
  • HTML page views : 7852
  • PDF downloads :76

Review summary

  1. Asifa
    Posted on Aug 24 2016 at 3:54 pm
    The article describes the role of cell replacement in the treatment of myocardial infraction and heart failure. The approach involves replacement of the damaged cardiomycetes with stem cells or pluripotent stem cell derived cardiomycetes for the complete recovery of structure and function of the heart cells. The article provides insights into this novel method and will help in the development of new and highly advanced methods of treatment of cardiovascular diseases.

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version